Ofelia Loani Elvir-Lazo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ofelia Loani Elvir-Lazo has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Paul F. White
FANZCA Cedars Sinai Medical Center, Department of Anesthesiology, 8700 Beverly Blvd, Los Angeles, CA 90048, United States of America; The White Mountain Institute, The Sea Ranch, CA 95497, United States of America
4 shared publications - Roya Yumul
Department of Anesthesiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
4 shared publications Robert Wong
Department of Anesthesiology, Cedars-Sinai Medical Center
3 shared publications- Roya Yumul
Department of Anesthesiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; David Geffen School of Medicine-UCLA, Charles R, Drew University of Medicine and Science, Los Angeles, CA, USA
3 shared publications David Chernobylsky
2 shared publications- Firuz Yumul
Department of family medicine, Skagit Regional Health, Family Medicine, Arlington, WA, USA
2 shared publications
Latest Publications
- Open Access
- 31 March 2026
- Published by Frontiers Media SA in Frontiers in Anesthesiology
- Vol. 5, 1766035
The anesthesiologist's role in preventing chronic post-surgical pain and opioid use through neurobiological programming: a mini review
Background: Chronic Post-Surgical Pain (CPSP) and Postoperative Chronic Opioid Use (COU) pose significant public health challenges. Anesthesiologists play a vital role in modulating acute pain during surgery and influencing its chronic trajectory. CPSP is defined as pain persisting for ≥3 months, localized to the surgical field or relevant nerve territory, and with other causes excluded. COU, a surrogate marker for prolonged utilization, is defined as prolonged utilization (≥10 prescriptions or ≥120 days’ supply) in the postsurgical year, excluding the initial 90 postoperative days. This mini-review synthesizes evidence on perioperative risk factors, mechanistic pathways, and anesthetic/analgesic interventions to influence the development of CPSP and COU. Methods: We performed a narrative literature review (February 2000–December 2025) across PubMed and Google Scholar, focusing on risk factors and mitigation strategies for CPSP and COU. Key search terms included “CPSP,” “COU,” “multimodal analgesia,” “neuroinflammation,” “epigenetic changes,” “TIVA,” and “precision medicine.” The search prioritized randomized controlled trials, systematic reviews, and key preclinical studies. Results: Chronicity is highly predictable based on preoperative psychosocial factors (e.g., anxiety, catastrophizing) and phenotypic hyperalgesia. Key mechanisms include central sensitization, neuroinflammation, epigenetic molecular programming, and gut-brain axis disruption. Evidence supports regional anesthesia (e.g., neuroaxial/paravertebral blocks) for CPSP prevention in high-risk procedures and targeted systemic non-opioids to mitigate opioid consumption and chronicity. Conclusions: CPSP and COU require a precision medicine approach that accounts for individual variability. This necessitates thorough preoperative risk stratification and the implementation of targeted, mechanism-based perioperative analgesia to intercept the neurobiological programming underlying chronic pain and opioid dependence.
- 31 March 2026
- Published by Frontiers Media SA in Frontiers in Anesthesiology
- Vol. 5, 1766035
Open AccessThe anesthesiologist's role in preventing chronic post-surgical pain and opioid use through neurobiological programming: a mini review
Background: Chronic Post-Surgical Pain (CPSP) and Postoperative Chronic Opioid Use (COU) pose significant public health challenges. Anesthesiologists play a vital role in modulating acute pain during surgery and influencing its chronic trajectory. CPSP is defined as pain persisting for ≥3 months, localized to the surgical field or relevant nerve territory, and with other causes excluded. COU, a surrogate marker for prolonged utilization, is defined as prolonged utilization (≥10 prescriptions or ≥120 days’ supply) in the postsurgical year, excluding the initial 90 postoperative days. This mini-review synthesizes evidence on perioperative risk factors, mechanistic pathways, and anesthetic/analgesic interventions to influence the development of CPSP and COU. Methods: We performed a narrative literature review (February 2000–December 2025) across PubMed and Google Scholar, focusing on risk factors and mitigation strategies for CPSP and COU. Key search terms included “CPSP,” “COU,” “multimodal analgesia,” “neuroinflammation,” “epigenetic changes,” “TIVA,” and “precision medicine.” The search prioritized randomized controlled trials, systematic reviews, and key preclinical studies. Results: Chronicity is highly predictable based on preoperative psychosocial factors (e.g., anxiety, catastrophizing) and phenotypic hyperalgesia. Key mechanisms include central sensitization, neuroinflammation, epigenetic molecular programming, and gut-brain axis disruption. Evidence supports regional anesthesia (e.g., neuroaxial/paravertebral blocks) for CPSP prevention in high-risk procedures and targeted systemic non-opioids to mitigate opioid consumption and chronicity. Conclusions: CPSP and COU require a precision medicine approach that accounts for individual variability. This necessitates thorough preoperative risk stratification and the implementation of targeted, mechanism-based perioperative analgesia to intercept the neurobiological programming underlying chronic pain and opioid dependence.
- Open Access
- 3 March 2026
- Published by Australian College of Perioperative Nurses in Journal of Perioperative Nursing
- Vol. 39 (1) , 20–28
Relationship between patients’ pre-operative anxiety level and administration of anxiolytic premedication
Objective: To evaluate the relationship between the patient’s reported level of pre-operative anxiety, the anaesthesiologist’s assessment of the patients’ anxiety level and the administration of anxiolytic premedication in the immediate pre-operative period. Methods: Patients' pre-operative anxiety level was self-assessed using a simple visual analog scale (0 = no anxiety to 10 = severe anxiety) in the pre-operative holding area. The anaesthesiologist independently visually assessed the patient’s level of anxiety on a similar 0 to 10 anxiety rating scale at the time of their pre-operative interview. Immediately after this, the anaesthesiologist decided whether to administer an anxiolytic medication prior to the patient entering the operating room. Results: Based on the anxiety scores reported by patients on the numeric analog scale, 58% (n=171) reported no-to-low levels of anxiety (scores ≤3) and 42% (n=122) reported moderate-to-high levels of anxiety (scores ≥4). According to the observational assessment by the anaesthesiologists, 70% of the patients were assigned an anxiety score ≤3 and 30% were assigned an anxiety score ≥4. Overall, 188 out of the 293 patients (64%) received a parenteral anxiolytic premedication. However, only 50% (61/122) of the patients reporting moderate-to-high levels of anxiety received an anxiolytic medication prior to entering the operating room. Surprisingly, 74% (127/171) of the patients reporting little or no anxiety were administered an anxiolytic drug. Interestingly, there was no significant difference in the average anxiety scores of patients who did or did not receive anxiolytic premedication (3.6±2.6 vs. 3.0±2.2, p= 0.11). Conclusions: These data suggest there is poor correlation between the patient’s reported level of pre-operative anxiety and the administration of anxiolytic medication. A more targeted approach to administering anxiolytic premedication based on the patient’s self-reported anxiety level in the pre-operative holding area would lead to more rationale use of anxiolytic medication prior to the patient entering the operating room.
- 3 March 2026
- Published by Australian College of Perioperative Nurses in Journal of Perioperative Nursing
- Vol. 39 (1) , 20–28
Open AccessRelationship between patients’ pre-operative anxiety level and administration of anxiolytic premedication
Objective: To evaluate the relationship between the patient’s reported level of pre-operative anxiety, the anaesthesiologist’s assessment of the patients’ anxiety level and the administration of anxiolytic premedication in the immediate pre-operative period. Methods: Patients' pre-operative anxiety level was self-assessed using a simple visual analog scale (0 = no anxiety to 10 = severe anxiety) in the pre-operative holding area. The anaesthesiologist independently visually assessed the patient’s level of anxiety on a similar 0 to 10 anxiety rating scale at the time of their pre-operative interview. Immediately after this, the anaesthesiologist decided whether to administer an anxiolytic medication prior to the patient entering the operating room. Results: Based on the anxiety scores reported by patients on the numeric analog scale, 58% (n=171) reported no-to-low levels of anxiety (scores ≤3) and 42% (n=122) reported moderate-to-high levels of anxiety (scores ≥4). According to the observational assessment by the anaesthesiologists, 70% of the patients were assigned an anxiety score ≤3 and 30% were assigned an anxiety score ≥4. Overall, 188 out of the 293 patients (64%) received a parenteral anxiolytic premedication. However, only 50% (61/122) of the patients reporting moderate-to-high levels of anxiety received an anxiolytic medication prior to entering the operating room. Surprisingly, 74% (127/171) of the patients reporting little or no anxiety were administered an anxiolytic drug. Interestingly, there was no significant difference in the average anxiety scores of patients who did or did not receive anxiolytic premedication (3.6±2.6 vs. 3.0±2.2, p= 0.11). Conclusions: These data suggest there is poor correlation between the patient’s reported level of pre-operative anxiety and the administration of anxiolytic medication. A more targeted approach to administering anxiolytic premedication based on the patient’s self-reported anxiety level in the pre-operative holding area would lead to more rationale use of anxiolytic medication prior to the patient entering the operating room.
- Open Access
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Anesthesiology
- Vol. 5, 1727481
Precision anesthesia and pharmacogenomics: a scoping review of personalized drug response
Background: Anesthetic agent selection and dosing have historically relied on empirical models without taking into account inter-individual variability in drug response, leading to adverse drug reactions (ADRs). Precision medicine, specifically leveraging pharmacogenomics (PGx), offers a paradigm shift toward personalized anesthesia, enhancing efficacy and safety. Methods: This scoping review synthesized literature from 2015 to 2025, using systematic database searches and Artificial Intelligence (AI)-powered tools, to identify the most extensively studied genetic variants impacting the pharmacokinetics and pharmacodynamics of common perioperative medications. Results: Key genetic variants in metabolic enzymes, transporters, and receptors significantly influence anesthetic outcomes. Examples include Reduced Metabolism/Prolonged Effects: Variations in CYP3A4/5 and POR alter midazolam metabolism, risking prolonged sedation. CYP2B6*6 is associated with decreased clearance of propofol and ketamine. BChE deficiency causes significantly prolonged paralysis with succinylcholine. Altered Efficacy/Increased Dose Requirements: OPRM1 118 A > G (G-allele) carriers show a blunted response to morphine, requiring higher doses. CYP2D6 ultra-rapid metabolizers (UMs) can have reduced efficacy of ondansetron and risk toxicity from pro-drugs like codeine and tramadol. Pathogenic mutations in RYR1 and CACNA1S identify patients susceptible to Malignant Hyperthermia from volatile anesthetics. Drug-Drug Interactions (DDIs): PGx overlaps with chronic medications (e.g., antidepressants, beta-blockers) that inhibit CYP2D6 , creating a phenoconversion risk that functionally mimics a Poor Metabolizer (PM) phenotype, drastically altering opioid efficacy. Conclusions: PGx holds transformative potential for the field of anesthesiology by offering actionable insights for drug selection and dose adjustment to mitigate ADRs and optimize pain control.
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Anesthesiology
- Vol. 5, 1727481
Open AccessPrecision anesthesia and pharmacogenomics: a scoping review of personalized drug response
Background: Anesthetic agent selection and dosing have historically relied on empirical models without taking into account inter-individual variability in drug response, leading to adverse drug reactions (ADRs). Precision medicine, specifically leveraging pharmacogenomics (PGx), offers a paradigm shift toward personalized anesthesia, enhancing efficacy and safety. Methods: This scoping review synthesized literature from 2015 to 2025, using systematic database searches and Artificial Intelligence (AI)-powered tools, to identify the most extensively studied genetic variants impacting the pharmacokinetics and pharmacodynamics of common perioperative medications. Results: Key genetic variants in metabolic enzymes, transporters, and receptors significantly influence anesthetic outcomes. Examples include Reduced Metabolism/Prolonged Effects: Variations in CYP3A4/5 and POR alter midazolam metabolism, risking prolonged sedation. CYP2B6*6 is associated with decreased clearance of propofol and ketamine. BChE deficiency causes significantly prolonged paralysis with succinylcholine. Altered Efficacy/Increased Dose Requirements: OPRM1 118 A > G (G-allele) carriers show a blunted response to morphine, requiring higher doses. CYP2D6 ultra-rapid metabolizers (UMs) can have reduced efficacy of ondansetron and risk toxicity from pro-drugs like codeine and tramadol. Pathogenic mutations in RYR1 and CACNA1S identify patients susceptible to Malignant Hyperthermia from volatile anesthetics. Drug-Drug Interactions (DDIs): PGx overlaps with chronic medications (e.g., antidepressants, beta-blockers) that inhibit CYP2D6 , creating a phenoconversion risk that functionally mimics a Poor Metabolizer (PM) phenotype, drastically altering opioid efficacy. Conclusions: PGx holds transformative potential for the field of anesthesiology by offering actionable insights for drug selection and dose adjustment to mitigate ADRs and optimize pain control.
- Open Access
- 4 November 2025
- Published by Frontiers Media SA in Frontiers in Anesthesiology
- Vol. 4, 1714040
Opioid-free anesthesia: a scoping review of efficacy, safety, and implementation challenges
Background: Opioid-free anesthesia (OFA) is a multimodal strategy to avoid intraoperative opioids and minimize associated complications, though evidence remains variable. Methods: A systematic search of PubMed and Google Scholar (2010–2025), supplemented by AI tools (Google Gemini) for earlier publications, summarized eligible studies (RCTs, cohorts, systematic reviews, and meta-analyses) comparing OFA to opioid-based anesthesia (OBA). Data were summarized following PRISMA-ScR guidelines. Results: Across 23 randomized controlled trials and one cohort study, OFA consistently reduced PONV, while demonstrating analgesia and recovery outcomes comparable to OBA. Hemodynamic stability was variable, with dexmedetomidine-based OFA regimens sometimes associated with increased bradycardia and hypotension. PACU stay varied, ranging from 9 min shorter to 15–35 min longer with OFA. Long-term outcome data are limited. Conclusion: OFA is a feasible approach that significantly reduces PONV while maintaining comparable analgesia and recovery. However, heterogeneous protocols, small sample sizes, and scarce long-term data limit external validity. Large, multicenter trials are needed to standardize OFA protocols and clarify long-term outcomes.
- 4 November 2025
- Published by Frontiers Media SA in Frontiers in Anesthesiology
- Vol. 4, 1714040
Open AccessOpioid-free anesthesia: a scoping review of efficacy, safety, and implementation challenges
Background: Opioid-free anesthesia (OFA) is a multimodal strategy to avoid intraoperative opioids and minimize associated complications, though evidence remains variable. Methods: A systematic search of PubMed and Google Scholar (2010–2025), supplemented by AI tools (Google Gemini) for earlier publications, summarized eligible studies (RCTs, cohorts, systematic reviews, and meta-analyses) comparing OFA to opioid-based anesthesia (OBA). Data were summarized following PRISMA-ScR guidelines. Results: Across 23 randomized controlled trials and one cohort study, OFA consistently reduced PONV, while demonstrating analgesia and recovery outcomes comparable to OBA. Hemodynamic stability was variable, with dexmedetomidine-based OFA regimens sometimes associated with increased bradycardia and hypotension. PACU stay varied, ranging from 9 min shorter to 15–35 min longer with OFA. Long-term outcome data are limited. Conclusion: OFA is a feasible approach that significantly reduces PONV while maintaining comparable analgesia and recovery. However, heterogeneous protocols, small sample sizes, and scarce long-term data limit external validity. Large, multicenter trials are needed to standardize OFA protocols and clarify long-term outcomes.
- Open Access
Challenges in achieving more sustainable anaesthesia practices: a narrative review of waste reduction
- Open Access
- 12 April 2024
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 95, 111473
Use of herbal medication in the perioperative period: Potential adverse drug interactions
- 12 April 2024
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 95, 111473
Open AccessUse of herbal medication in the perioperative period: Potential adverse drug interactions
- 30 September 2021
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 133 (8) , 939-952
Impact of chronic medications in the perioperative period: mechanisms of action and adverse drug effects (Part I)
Background: This review article discusses the pharmacology of the most commonly used chronic medications in patients undergoing elective surgical procedures. The mechanism of action and adverse side effects of cardiovascular medications (e.g., beta blockers, alpha-2 agonist, calcium channel blockers, ACE inhibitors, diuretics), lipid-lowering drugs, gastrointestinal medications (H2-blockers, proton pump inhibitors), pulmonary medications (inhaled β-agonists, anticholinergics,), antibiotics (tetracyclines, clindamycin and macrolide, linezolid), opioids and non-opioids analgesics (NSAIDs, COX-2 inhibitors, acetaminophen), gabapentanoids, erectile dysfunction (ED) drugs, and psychotropic drugs (tricyclic antidepressants [TCAs], monoamine oxidase inhibitors [MAOI], selective serotonin reuptake inhibitors [SSRIs], serotonin norepinephrine reuptake inhibitors [SNRIs], and cannabinol-containing drugs) will be reviewed. Materials and Methods: An online search was conducted from January 2000 through February 2021 with the Medline database through PubMed and Google Scholar using the following search terms/keywords: “chronic medications in the perioperative period”, and “chronic medications and anesthetic implications.” In addition, we searched for anesthetic side effects associated with the major drug groups. Results and Conclusions: An understanding of the pharmacology and pharmacokinetics of most used chronic medications is important to avoid untoward outcomes in the perioperative period. These drug interactions may result in altered efficacy and toxicity of the anesthetic medications administered during surgery. These drug-drug interactions can also effect the morbidity, mortality, and recovery time of surgical patients. Part I of this two-part review article focuses on the mechanisms of action and adverse side effects of the chronic medications most commonly taken by surgical patients in the preoperative period.
- 30 September 2021
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 133 (8) , 939-952
Impact of chronic medications in the perioperative period: mechanisms of action and adverse drug effects (Part I)
Background: This review article discusses the pharmacology of the most commonly used chronic medications in patients undergoing elective surgical procedures. The mechanism of action and adverse side effects of cardiovascular medications (e.g., beta blockers, alpha-2 agonist, calcium channel blockers, ACE inhibitors, diuretics), lipid-lowering drugs, gastrointestinal medications (H2-blockers, proton pump inhibitors), pulmonary medications (inhaled β-agonists, anticholinergics,), antibiotics (tetracyclines, clindamycin and macrolide, linezolid), opioids and non-opioids analgesics (NSAIDs, COX-2 inhibitors, acetaminophen), gabapentanoids, erectile dysfunction (ED) drugs, and psychotropic drugs (tricyclic antidepressants [TCAs], monoamine oxidase inhibitors [MAOI], selective serotonin reuptake inhibitors [SSRIs], serotonin norepinephrine reuptake inhibitors [SNRIs], and cannabinol-containing drugs) will be reviewed. Materials and Methods: An online search was conducted from January 2000 through February 2021 with the Medline database through PubMed and Google Scholar using the following search terms/keywords: “chronic medications in the perioperative period”, and “chronic medications and anesthetic implications.” In addition, we searched for anesthetic side effects associated with the major drug groups. Results and Conclusions: An understanding of the pharmacology and pharmacokinetics of most used chronic medications is important to avoid untoward outcomes in the perioperative period. These drug interactions may result in altered efficacy and toxicity of the anesthetic medications administered during surgery. These drug-drug interactions can also effect the morbidity, mortality, and recovery time of surgical patients. Part I of this two-part review article focuses on the mechanisms of action and adverse side effects of the chronic medications most commonly taken by surgical patients in the preoperative period.
- 30 September 2021
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 133 (8) , 920-938
Impact of chronic medications in the perioperative period –anesthetic implications (Part II)
Background: This review article discusses the pharmacodynamic effects of the most commonly used chronic medications by patients undergoing elective surgical procedures, namely cardiovascular drugs (e.g., beta blockers, alpha-2 agonist, calcium channel blockers, ACE inhibitors, diuretics, etc.), lipid-lowering drugs, gastrointestinal medications (H2-blockers, proton pump inhibitors), pulmonary medications (inhaled β-agonists, anticholinergics,), antibiotics (tetracyclines, clindamycin and macrolide, linezolid.), opioids and non-opioids analgesics (NSAIDs, COX-2 inhibitors, acetaminophen), gabapentanoids, erectile dysfunction (ED) drugs, psychotropic drugs (tricyclic antidepressants [TCAs], monoamine oxidase inhibitors [MAOI], selective serotonin reuptake inhibitors [SSRIs], serotonin norepinephrine reuptake inhibitors [SNRIs], and cannabinol-containing drugs). In addition, the potential adverse drug-interactions between these chronic medications and commonly used anesthetic drugs during the perioperative period will be reviewed. Finally, recommendations regarding the management of chronic medications during the preoperative period will be provided. Materials and Methods: An online search was conducted from January 2000 through February 2021 with the Medline database through PubMed and Google Scholar using the following search terms/keywords: “chronic medications in the perioperative period”, and “chronic medications and anesthetic implications.” In addition, we searched for anesthetic side effects associated with the major drug groups. Results and Conclusions: An understanding of the pharmacodynamic effects of most used chronic medications is important to avoid untoward outcomes in the perioperative period. These drug interactions may result in altered efficacy and toxicity of the anesthetic medications administered during surgery. These drug-drug interactions can also affect the morbidity, mortality, recovery time of surgical patients and acute relapse of chronic illnesses which could lead to last minute cancellation of surgical procedures. Part II of this two-part review article focuses on the reported interactions between most commonly taken chronic medications by surgical patients and anesthetic and analgesic drugs, as well as recommendations regarding the handling these chronic medications during the perioperative period.
- 30 September 2021
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 133 (8) , 920-938
Impact of chronic medications in the perioperative period –anesthetic implications (Part II)
Background: This review article discusses the pharmacodynamic effects of the most commonly used chronic medications by patients undergoing elective surgical procedures, namely cardiovascular drugs (e.g., beta blockers, alpha-2 agonist, calcium channel blockers, ACE inhibitors, diuretics, etc.), lipid-lowering drugs, gastrointestinal medications (H2-blockers, proton pump inhibitors), pulmonary medications (inhaled β-agonists, anticholinergics,), antibiotics (tetracyclines, clindamycin and macrolide, linezolid.), opioids and non-opioids analgesics (NSAIDs, COX-2 inhibitors, acetaminophen), gabapentanoids, erectile dysfunction (ED) drugs, psychotropic drugs (tricyclic antidepressants [TCAs], monoamine oxidase inhibitors [MAOI], selective serotonin reuptake inhibitors [SSRIs], serotonin norepinephrine reuptake inhibitors [SNRIs], and cannabinol-containing drugs). In addition, the potential adverse drug-interactions between these chronic medications and commonly used anesthetic drugs during the perioperative period will be reviewed. Finally, recommendations regarding the management of chronic medications during the preoperative period will be provided. Materials and Methods: An online search was conducted from January 2000 through February 2021 with the Medline database through PubMed and Google Scholar using the following search terms/keywords: “chronic medications in the perioperative period”, and “chronic medications and anesthetic implications.” In addition, we searched for anesthetic side effects associated with the major drug groups. Results and Conclusions: An understanding of the pharmacodynamic effects of most used chronic medications is important to avoid untoward outcomes in the perioperative period. These drug interactions may result in altered efficacy and toxicity of the anesthetic medications administered during surgery. These drug-drug interactions can also affect the morbidity, mortality, recovery time of surgical patients and acute relapse of chronic illnesses which could lead to last minute cancellation of surgical procedures. Part II of this two-part review article focuses on the reported interactions between most commonly taken chronic medications by surgical patients and anesthetic and analgesic drugs, as well as recommendations regarding the handling these chronic medications during the perioperative period.
- Top Cited PapersOpen Access
- 13 August 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 983
Management strategies for the treatment and prevention of postoperative/postdischarge nausea and vomiting: an updated review
Postoperative nausea and vomiting (PONV) and postdischarge nausea and vomiting (PDNV) remain common and distressing complications following surgery. The routine use of opioid analgesics for perioperative pain management is a major contributing factor to both PONV and PDNV after surgery. PONV and PDNV can delay discharge from the hospital or surgicenter, delay the return to normal activities of daily living after discharge home, and increase medical costs. The high incidence of PONV and PDNV has persisted despite the introduction of many new antiemetic drugs (and more aggressive use of antiemetic prophylaxis) over the last two decades as a result of growth in minimally invasive ambulatory surgery and the increased emphasis on earlier mobilization and discharge after both minor and major surgical procedures (e.g. enhanced recovery protocols). Pharmacologic management of PONV should be tailored to the patient’s risk level using the validated PONV and PDNV risk-scoring systems to encourage cost-effective practices and minimize the potential for adverse side effects due to drug interactions in the perioperative period. A combination of prophylactic antiemetic drugs with different mechanisms of action should be administered to patients with moderate to high risk of developing PONV. In addition to utilizing prophylactic antiemetic drugs, the management of perioperative pain using opioid-sparing multimodal analgesic techniques is critically important for achieving an enhanced recovery after surgery. In conclusion, the utilization of strategies to reduce the baseline risk of PONV (e.g. adequate hydration and the use of nonpharmacologic antiemetic and opioid-sparing analgesic techniques) and implementing multimodal antiemetic and analgesic regimens will reduce the likelihood of patients developing PONV and PDNV after surgery.
- 13 August 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 983
Top Cited PapersOpen AccessManagement strategies for the treatment and prevention of postoperative/postdischarge nausea and vomiting: an updated review
Postoperative nausea and vomiting (PONV) and postdischarge nausea and vomiting (PDNV) remain common and distressing complications following surgery. The routine use of opioid analgesics for perioperative pain management is a major contributing factor to both PONV and PDNV after surgery. PONV and PDNV can delay discharge from the hospital or surgicenter, delay the return to normal activities of daily living after discharge home, and increase medical costs. The high incidence of PONV and PDNV has persisted despite the introduction of many new antiemetic drugs (and more aggressive use of antiemetic prophylaxis) over the last two decades as a result of growth in minimally invasive ambulatory surgery and the increased emphasis on earlier mobilization and discharge after both minor and major surgical procedures (e.g. enhanced recovery protocols). Pharmacologic management of PONV should be tailored to the patient’s risk level using the validated PONV and PDNV risk-scoring systems to encourage cost-effective practices and minimize the potential for adverse side effects due to drug interactions in the perioperative period. A combination of prophylactic antiemetic drugs with different mechanisms of action should be administered to patients with moderate to high risk of developing PONV. In addition to utilizing prophylactic antiemetic drugs, the management of perioperative pain using opioid-sparing multimodal analgesic techniques is critically important for achieving an enhanced recovery after surgery. In conclusion, the utilization of strategies to reduce the baseline risk of PONV (e.g. adequate hydration and the use of nonpharmacologic antiemetic and opioid-sparing analgesic techniques) and implementing multimodal antiemetic and analgesic regimens will reduce the likelihood of patients developing PONV and PDNV after surgery.
- Open Access
- 21 December 2017
- Published by F1000 Research Ltd in F1000Research
- Vol. 6, 2161
Use of electroanalgesia and laser therapies as alternatives to opioids for acute and chronic pain management
The use of opioid analgesics for postoperative pain management has contributed to the global opioid epidemic. It was recently reported that prescription opioid analgesic use often continued after major joint replacement surgery even though patients were no longer experiencing joint pain. The use of epidural local analgesia for perioperative pain management was not found to be protective against persistent opioid use in a large cohort of opioid-naïve patients undergoing abdominal surgery. In a retrospective study involving over 390,000 outpatients more than 66 years of age who underwent minor ambulatory surgery procedures, patients receiving a prescription opioid analgesic within 7 days of discharge were 44% more likely to continue using opioids 1 year after surgery. In a review of 11 million patients undergoing elective surgery from 2002 to 2011, both opioid overdoses and opioid dependence were found to be increasing over time. Opioid-dependent surgical patients were more likely to experience postoperative pulmonary complications, require longer hospital stays, and increase costs to the health-care system. The Centers for Disease Control and Prevention emphasized the importance of finding alternatives to opioid medication for treating pain. In the new clinical practice guidelines for back pain, the authors endorsed the use of non-pharmacologic therapies. However, one of the more widely used non-pharmacologic treatments for chronic pain (namely radiofrequency ablation therapy) was recently reported to have no clinical benefit. Therefore, this clinical commentary will review evidence in the peer-reviewed literature supporting the use of electroanalgesia and laser therapies for treating acute pain, cervical (neck) pain, low back pain, persistent post-surgical pain after spine surgery (“failed back syndrome”), major joint replacements, and abdominal surgery as well as other common chronic pain syndromes (for example, myofascial pain, peripheral neuropathic pain, fibromyalgia, degenerative joint disease/osteoarthritis, and migraine headaches).
- 21 December 2017
- Published by F1000 Research Ltd in F1000Research
- Vol. 6, 2161
Open AccessUse of electroanalgesia and laser therapies as alternatives to opioids for acute and chronic pain management
The use of opioid analgesics for postoperative pain management has contributed to the global opioid epidemic. It was recently reported that prescription opioid analgesic use often continued after major joint replacement surgery even though patients were no longer experiencing joint pain. The use of epidural local analgesia for perioperative pain management was not found to be protective against persistent opioid use in a large cohort of opioid-naïve patients undergoing abdominal surgery. In a retrospective study involving over 390,000 outpatients more than 66 years of age who underwent minor ambulatory surgery procedures, patients receiving a prescription opioid analgesic within 7 days of discharge were 44% more likely to continue using opioids 1 year after surgery. In a review of 11 million patients undergoing elective surgery from 2002 to 2011, both opioid overdoses and opioid dependence were found to be increasing over time. Opioid-dependent surgical patients were more likely to experience postoperative pulmonary complications, require longer hospital stays, and increase costs to the health-care system. The Centers for Disease Control and Prevention emphasized the importance of finding alternatives to opioid medication for treating pain. In the new clinical practice guidelines for back pain, the authors endorsed the use of non-pharmacologic therapies. However, one of the more widely used non-pharmacologic treatments for chronic pain (namely radiofrequency ablation therapy) was recently reported to have no clinical benefit. Therefore, this clinical commentary will review evidence in the peer-reviewed literature supporting the use of electroanalgesia and laser therapies for treating acute pain, cervical (neck) pain, low back pain, persistent post-surgical pain after spine surgery (“failed back syndrome”), major joint replacements, and abdominal surgery as well as other common chronic pain syndromes (for example, myofascial pain, peripheral neuropathic pain, fibromyalgia, degenerative joint disease/osteoarthritis, and migraine headaches).